Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The final quarter of 2025 saw an avalanche of critical trial results and 

, the FDA brought about substantial progress across the scope of cardiology during the last 3 months.

Trial data from SELECT, ATTRibute-CM, and other key studies were also released during this quarter, with drugs like olezarsen and baxdrostat advancing rapidly through the pipeline while semaglutide achieved a groundbreaking new indication in cardiovascular care.

 has collected 10 of the most impactful headlines from Q4 of 2025 – check them out below:


FDA Approves Updated Indication for Sotatercept-csrk (WINREVAIR) in Adult PAH


On October 27, 2025, the FDA approved an updated indication for sotatercept-csrk, allowing for its use in treating pulmonary arterial hypertension (PAH) in adult patients. While sotatercept was previously approved to improve exercise capacity and WHO functional class, data from the phase 3 ZENITH study highlighted its capacity to reduce risk of composite death from any cause, lung transplantation, or hospitalization for worsening PAH.


FDA Approves Plozasiran for Adults With Familial Chylomicronemia Syndrome


On November 18, 2025, Arrowhead Pharmaceuticals announced the FDA’s approval of plozasiran for the reduction of triglycerides in adult patients with familial chylomicronemia syndrome (FCS). The first-in-class RNA interference therapeutic displayed its efficacy in the PALISADE phase 3 trial, where it outperformed placebo in reducing triglycerides and acute pancreatitis risk. Plozasiran also exhibited a favorable tolerability profile throughout the trial.


FDA Approves Etripamil (Cardamyst) Nasal Spray for PSVT


On December 12, 2025, the FDA approved etripamil nasal spray for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. This is the first fast-acting, self-administered treatment for PSVT, which is predicted to substantially lower the number of hospitalizations or emergency department visits for abnormal sinus rhythms. The FDA’s decision was based on a wide range of trials, a collective analysis of which revealed a significantly greater percentage of patients achieved normal sinus rhythm with etripamil compared to placebo.


FDA Approves Lerodalcibep-liga (Lerochol) for LDL-C Reduction in Hypercholesterolemia


Lerodalcibep-liga received its FDA approval on December 15, 2025, as a result of positive data from the LIBerate program. This was a series of 5 global phase 3 registration studies which highlighted the small protein-binding third-generation PSCK9 inhibitor’s capacity for LDL-C lowering in patients with hypercholesterolemia. Most recently, the LIBerate-HoFH phase 3 trial indicated lerodalcibep’s noninferiority to evolocumab, with a 9.1% average decrease in LDL-C from lerodalcibep and a 10.8% average decrease in evolocumab.


FDA Approves Aficamten (Myqorzo) for Symptomatic Obstructive Hypertrophic Cardiomyopathy


Aficamten received FDA approval for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) on December 19, 2025, based on data from the phase 3 SEQUOIA-HCM trial. During this study, patients taking aficamten demonstrated superior exercise capacity improvements compared to those on placebo, as well as increased peak oxygen uptake. Aficamten was also well tolerated, with no instances of worsening heart failure or treatment interruptions due to LVEF.


Bax24: Baxdrostat Achieves Primary Endpoint in Treatment-Resistant Hypertension


The Bax24 phase 3 trial saw baxdrostat, a first-in-class, highly potent and selective oral small molecule designed by AstraZeneca to inhibit aldosterone synthase, achieve its primary endpoint of a statistically significant reduction in ambulatory 24-hour average systolic blood pressure (SBP) in patients with treatment-resistant hypertension (rHTN). The randomized, double-blind, placebo-controlled, parallel group study compared baxdrostat to placebo in 218 patients over 12 weeks.


SELECT: Semaglutide Indicates Possible Cardiovascular Disease-Modifying Effect


The SELECT phase 3 trial saw semaglutide outperform placebo in reducing the risk of major adverse cardiovascular events in patients with established 

atherosclerotic cardiovascular disease (ASCVD)

. This cardioprotective effect would go on to provide evidence for the later FDA approval of oral semaglutide for a cardiovascular indication, marking the first oral GLP-1 to cross over into cardiology.


ATTRibute-CM: Acoramidis Reduces Cardiovascular Mortality and Hospitalization, With Ahmad Masri, MD

ATTRibute-CM: Acoramidis Reduces Cardiovascular Mortality and Hospitalization with Ahmad Masri, MD

The phase 3 ATTRibute-CM trial saw acoramidis substantially reduce cumulative cardiovascular mortality and recurrent cardiovascular-related hospitalization over 30 months in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). These data were presented at the Heart Failure Society of America Scientific Meeting by Ahmad Masri, MD, director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University.


CORE/CORE2: Olezarsen Achieves Primary Endpoint in Severe Hypertriglyceridemia


During the CORE and CORE2 phase 3 trials, investigative antisense oligonucleotide olezarsen achieved its primary endpoint of a highly significant mean reduction in fasting triglyceride levels in patients with severe hypertriglyceridemia. This result was sustained through the full 12-month duration, indicating olezarsen’s superiority to placebo.


CeleBrate: Zalunfiban Administration at First Contact Improves STEMI Outcomes, With C. Michael Gibson, MD


During the CeleBrate trial, subcutaneous glycoprotein IIb/IIIa inhibitor zalunfiban successfully achieved its primary efficacy endpoint, a hierarchical proportional odds model ranking all-cause death, 

, recurrent myocardial infarction, acute stent thrombosis, new-onset or re-hospitalization for heart failure, larger infarct size, or no endpoint through 30 days. Should this lead to an FDA approval in the future, zalunfiban could revolutionize treatment for patients with suspected ST-segment elevation myocardial infarction.

Articles

The final quarter of 2025 marked significant advancements in cardiology, with numerous FDA approvals and pivotal trial results. Key developments included the approval of sotatercept-csrk for pulmonary arterial hypertension, plozasiran for familial chylomicronemia syndrome, and etripamil nasal spray for PSVT. Additionally, lerodalcibep-liga and aficamten received approvals for hypercholesterolemia and obstructive hypertrophic cardiomyopathy, respectively. Notable trial outcomes featured baxdrostat's efficacy in treatment-resistant hypertension, semaglutide's cardiovascular benefits, acoramidis's impact on ATTR-CM, olezarsen's triglyceride reduction, and zalunfiban's potential in STEMI management.

The Q4 recap for cardiology spotlights major FDA decisions, key clinical trial updates, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

Dyslipidemia

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Atherosclerotic Cardiovascular Disease

FDA News

Q4 2025 Recap: Cardiology News and Updates

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

December 2025 delivered a diverse set of advances across 

, spanning autoimmune neuromuscular disease, systemic lupus erythematosus (SLE), osteoarthritis, and chronic pain syndromes. Regulatory momentum was highlighted by the FDA approval of inebilizumab-cdon for generalized myasthenia gravis, while late-stage clinical data for orelabrutinib and retatrutide underscored continued progress toward more targeted, mechanism-driven therapies across inflammatory and metabolic–musculoskeletal disease.

At the same time, emerging nonpharmacologic and symptom-focused strategies gained visibility, particularly in fibromyalgia, where both neuromodulation with transcutaneous auricular vagus nerve stimulation and the recent approval of TNX-102 SL reflect a broader shift toward multimodal care. 

Check out this December 2025 rheumatology month in review for a recap of HCPLive’s coverage of the top news and research from the past few weeks:

FDA Approves Inebilizumab-cdon (Uplizna) for Generalized Myasthenia Gravis

On December 11, 2025, the FDA approved inebilizumab-cdon for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-AChR or anti-MuSK antibody positive, expanding treatment options with a targeted therapy. Supported by data from the phase 3 MINT trial, the CD19-targeting monoclonal antibody demonstrated durable improvements in disease activity with a twice-yearly maintenance dosing schedule following initial loading.

Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Trial

Orelabrutinib met its primary endpoint in a phase 2b, randomized, placebo-controlled trial, with significantly more patients with SLE achieving an SRI-4 response at week 48 with the 75 mg once-daily dose compared with placebo (57.1% vs 34.4%; 

 <.05), alongside improvements in SRI-6 and BICLA responses. The CNS-penetrant BTK inhibitor was generally well tolerated and has now received regulatory approval to advance into a phase 3 registrational trial, supporting its potential as a novel targeted therapy for SLE.

TRIUMPH-4: Retatrutide Delivers Weight Loss, Knee Osteoarthritis Pain Relief

Eli Lilly announced positive topline results from the phase 3 TRIUMPH-4 trial showing that investigational retatrutide 9 mg and 12 mg met all primary and key secondary endpoints in adults with obesity or overweight and knee osteoarthritis, significantly improving body weight, pain, and physical function at 68 weeks. The first-in-class GIP/GLP-1/glucagon triple agonist delivered up to nearly 29% average weight loss alongside substantial reductions in WOMAC pain scores, supporting its potential as a novel therapeutic option for obesity complicated by osteoarthritis.

taVNS Reduces Pain, Improves Mood in Fibromyalgia Patients

A recent study found that both left-sided and bilateral transcutaneous auricular vagus nerve stimulation (taVNS) significantly reduced pain and improved mood and functional outcomes in patients with fibromyalgia, with no meaningful differences in autonomic safety between approaches. The findings support taVNS as a safe, noninvasive adjunctive option for fibromyalgia management, though larger studies are needed to determine whether one stimulation strategy offers superior clinical benefit.

Reframing Fibromyalgia Care in 2025: Restricted Impact of TNX-102 SL’s Approval

The FDA approval of TNX-102 SL in August 2025 marked the first new fibromyalgia drug approval in more than 15 years, introducing a sleep-targeted, non-opioid approach aimed at addressing nonrestorative sleep as a core driver of symptoms. Clinicians view the therapy as a meaningful but incremental advance that may benefit selected patients when integrated into multimodal care, rather than a standalone solution for this complex, heterogeneous condition.

December 2025 saw significant advancements in rheumatology, including FDA approval of inebilizumab-cdon for generalized myasthenia gravis and promising late-stage data for orelabrutinib and retatrutide. These developments highlight a shift towards targeted, mechanism-driven therapies for inflammatory and metabolic–musculoskeletal diseases. Nonpharmacologic strategies, such as transcutaneous auricular vagus nerve stimulation for fibromyalgia, gained attention, reflecting a move towards multimodal care. The approval of TNX-102 SL for fibromyalgia emphasizes a sleep-targeted approach, offering incremental benefits within a comprehensive treatment strategy for this complex condition.

This rheumatology month in review emphasizes new data and impactful approvals.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Lupus

Gout

On the HCPLive gout page, resources on the topics of medical news and expert insight into gouty arthritis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on gout, and more.

Psoriatic Arthritis

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.

5 Rheumatology Headlines You Missed in December 2025

Pulmonology news in December 2025 closed the year with landmark regulatory advances that expanded treatment options for historically underserved respiratory diseases. FDA approvals of nerandomilast for idiopathic pulmonary fibrosis—the first new idiopathic pulmonary fibrosis (IPF) therapy in more than a decade—and depemokimab-ulaa for severe eosinophilic asthma highlighted parallel progress toward disease modification and reduced treatment burden, supported by robust phase 3 data demonstrating meaningful clinical benefit with favorable safety profiles.

Alongside these approvals, late-year data and expert commentary reinforced a broader shift toward precision, trait-based respiratory care. New evidence showing pulmonary rehabilitation can reduce type 2 airway inflammation in select asthma populations complemented discussions on biomarker-driven management across asthma and chronic obstructive pulmonary disease (COPD), while persistent gaps in COPD and lung cancer screening underscored that translating innovation into improved outcomes will also require better implementation of existing, evidence-based tools.

Check out this December 2025 pulmonology month in review for a recap of HCPLive’s coverage of the top news and research from the past few weeks:

Nerandomilast Nets First New FDA Approval for Idiopathic Pulmonary Fibrosis in Over 10 Years

The FDA has approved nerandomilast 9 mg and 18 mg (Jascayd; Boehringer Ingelheim) for adults with idiopathic pulmonary fibrosis, marking the first new IPF therapy approved in more than a decade. The decision was supported by phase 3 FIBRONEER-IPF data showing significantly reduced decline in forced vital capacity versus placebo, with a generally well-tolerated safety profile.

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

The FDA has approved GSK’s depemokimab-ulaa (Exdensur) as an add-on maintenance therapy for severe eosinophilic asthma in patients aged 12 years and older, introducing the first ultra–long-acting biologic in this space with twice-yearly dosing. The approval was supported by data from the phase 3 SWIFT-1 and SWIFT-2 trials demonstrating significant reductions inannualized asthma exacerbations compared with placebo while maintaining a safety profile comparable to standard of care.

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Pulmonary rehabilitation (PR) was shown to meaningfully reduce airway inflammation in people with asthma who began treatment with elevated FeNO, with the high-FeNO group experiencing a 40% drop in levels during the 3-week program. Improvements in asthma control and exercise capacity occurred across all baseline FeNO categories, but the anti-inflammatory effect was exclusive to those with high initial FeNO.
4. 

Rewriting Airway Disease With Trait-Based Care: 2025’s Convergence of Asthma and COPD Management

In this HCPLive expert discussion moderated by Joseph Khabbaza, MD, clinicians examine how the FDA approval of mepolizumab for eosinophilic COPD could mark a turning point in a field long limited to symptom-focused therapies. Drawing on phase 3 MATINEE data, the panel highlights its potential to reduce exacerbations, limit systemic steroid exposure, and usher COPD care toward a more asthma-like, biomarker-driven precision model.

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Despite well-established screening tools and expanded eligibility criteria, COPD and lung cancer remain profoundly underdiagnosed in the US, with most patients still identified at advanced stages when survival benefits are limited. Experts point to systemic access gaps, clinician hesitation, and persistent disease stigma as key barriers, underscoring that improving outcomes in 2026 will depend less on new technology than on using the tools already proven to work.

December 2025 marked significant regulatory advancements in pulmonology, with FDA approvals of nerandomilast for idiopathic pulmonary fibrosis and depemokimab-ulaa for severe eosinophilic asthma, both supported by robust phase 3 data. These approvals highlight a shift towards precision, trait-based respiratory care, emphasizing disease modification and reduced treatment burden. Pulmonary rehabilitation showed potential in reducing type 2 airway inflammation in asthma, while discussions on biomarker-driven management for asthma and COPD gained traction. However, challenges in COPD and lung cancer screening persist, necessitating better implementation of existing tools.

December 2025 saw new data on asthma therapies and new insights from experts on continuing trends in the field.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

5 Pulmonology Headlines You Missed in December 2025

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

 has a substantial effect on patients with 

, with new research suggesting it may accelerate disease progression, particularly in the early stages.

Additionally, the findings highlight a disproportionate diagnosis of depression in patients with end-stage kidney disease, with investigators suggesting there may be an increased psychological burden as kidney function declines.

“From a clinical standpoint, implementing systematic depression screening could meaningfully change CKD care pathways,” wrote study investigator Abdullah Al-Mamun, PhD, an Assistant Professor in the Department of Pharmaceutical Systems and Policy from the West Virginia University School of Pharmacy, and colleagues.

The previous literature in CKD has linked the disease burden to increased depression instances, and, in turn, adverse health outcomes. A 

 paired CKD and social frailty, especially in patients in advanced stages undergoing hemodialysis, with an increased risk of depression. Meanwhile, another study found CKD patients with depressive symptoms were more likely to initiate dialysis or experience all-cause mortality, pointing to a potential link between mental health and disease trajectory. Another study observed an association of depressive symptoms with a 2.25-fold higher risk of progression to dialysis over 3 years.

In this retrospective cohort analysis, Al-Mamun and colleagues aimed to further evaluate the association between depression and CKD, especially beginning with early stages. They extracted data from the TriNetX electronic medical record database of patients with a CKD diagnosis. The primary objective included key independent variables such as diagnosis of depression or anxiety, identified by ICD codes. Secondary objectives were CKD stages ≥ 3, 4, and 5, as defined by Kidney Disease Improving Global Outcomes (KDIGO).

The primary outcome was progression to kidney disease, with an eGFR < 60 ml/min/bsa and > 40% decline in eGFR from the initial screening, while the secondary outcome was diagnosis of depression.

The study included adults ≥ 18 years of age with baseline CKD at > 1 year of follow-up data. The primary objective cohort was dichotomized into depression or no depression, and the secondary objective cohort was categorized by CKD stages.

In Kaplan-Meier curve analysis, investigators found faster kidney disease progression in patients with depression compared to patients without (

<.0001). In the adjusted Cox model, depression was significantly associated with an increased risk of kidney disease progression 1.94 (95% Confidence Interval [CI], 1.77–2.11, 

Among the 3 CKD stage groups, the survival probability decreased most rapidly for patients in stage 5, followed by stage 4, and then stage ≤3, with investigators positing it indicates patients in more advanced stages of CKD are more likely to develop depression earlier. Additionally, the differences between the survival curves for the CKD stages were statistically significant (

<.0001), suggesting a strong association between CKD stage and the time to depression onset.

Furthermore, investigators reported an increased risk of developing depression in patients in stage 4 compared to those in stage ≤3 (Hazard Ratio [HR], 1.26 [1.17–1.35]; 

< .05), and those in Stage 5 had an even higher increase in risk (HR, 1.38 [1.23–1.54]; 

“The findings of this study underscore a significant association between depression and CKD progression, particularly in the earlier stages,” concluded investigators. “Our results show that patients with a diagnosis of depression following their CKD diagnosis had a higher likelihood of kidney disease progression compared to those without depression.”

Jeun KJ, Brothers T, Khaled Shawwa, Al-Mamun MA. A retrospective cohort study on the bidirectional association between depression and chronic kidney disease. Frontiers in Nephrology. 2026;5. doi:

https://doi.org/10.3389/fneph.2025.1743594

Gabriela D, Luma Geraigire, Ferreira S, et al. Predictors of Social Frailty and Depression in Brazilian Patients With Chronic Kidney Disease: A Cross‐Sectional Study. 

Geriatrics and gerontology international/Geriatrics & gerontology international

Shen Y, Chen Y, Huang S, Yao X, Kanwar YS, Zhan M. The Association between Symptoms of Depression and Anxiety, Quality of Life, and Diabetic Kidney Disease among Chinese Adults: A Cross-Sectional Study. 

International Journal of Environmental Research and Public Health

Zhang Z, He P, Liu M, et al. Association of Depressive Symptoms with Rapid Kidney Function Decline in Adults with Normal Kidney Function. 

Clinical Journal of the American Society of Nephrology

Depression significantly impacts chronic kidney disease (CKD) patients, potentially accelerating disease progression, especially in early stages. Research indicates a higher prevalence of depression in end-stage kidney disease, suggesting increased psychological burden as kidney function declines. Systematic depression screening could alter CKD care pathways. Studies link CKD burden to increased depression and adverse health outcomes, with depressive symptoms associated with higher dialysis initiation and mortality risks. A retrospective cohort analysis found depression significantly associated with faster CKD progression, particularly in advanced stages, highlighting the need for integrated mental health management in CKD care.

A retrospective cohort analysis reports data on a two-sided relationship between depression diagnosis and chronic kidney disease progression. 


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Depression's Implied Bilateral Link With Chronic Kidney Disease Progression

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The American Gastroenterological Association (AGA) has released a clinical practice update on the evaluation and management of refractory constipation.

, on January 7, 2025, outlines 14 best-practice advice statements to help clinicians accurately diagnose and manage refractory constipation and to identify which patients may benefit from surgical intervention.

Constipation is a common disorder affecting approximately 1 out of every 6-7 people worldwide, and annually leading to > 1.5 million healthcare provider visits in the United States alone. While clinicians today have a wide therapeutic armamentarium, including osmotic and stimulant laxatives, secretagogues, and prokinetic agents, as well as emerging device-based therapeutic approach designed to enhance colonic motility without pharmacologic action like the vibrating capsule, some patients still do not respond to treatment.

“Though most patients with chronic constipation respond to standard treatments, a subset remains refractory to available therapies and merit the designation of ‘refractory.’ Such patients consume significant healthcare resources and frequently present to tertiary care centers,” Kyle Staller, MD, MPH, director of the Gastrointestinal Motility Laboratory at Mass General., and colleagues wrote.

Commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board, the review is designed to provide best practice advice on 14 key clinical issues related to the diagnosis, treatment, and medical and surgical management of patients with refractory constipation.

Acknowledging that refractory constipation is relatively rare, the document recommends clinicians systematically exclude correctable secondary causes such as medications, neurologic disorders, and defecatory disorders, confirm the presence of slow colonic transit, and ensure that patients have undergone adequate trials of over-the-counter and Food and Drug Administration–approved medications and nonpharmacologic therapies, including combinations thereof.

While the update says surgical treatments like colectomy can be considered in patients who fail available treatments, the authors note surgical treatment of chronic constipation is associated with increased risk of complications and a not insignificant number of unsatisfactory outcomes. Prior to advising surgery, it is recommended that clinicians confirm slow colonic transit, exclude concurrent defecatory disorders, and evaluate for severe, symptomatic delays in gastric emptying or small bowel dysmotility.

Because psychological comorbidities may exacerbate symptoms and adversely affect surgical outcomes, preoperative psychological evaluation is advised to assess suitability for surgery.

Relative contraindications to surgical treatment of refractory constipation include clinically significant upper-gut dysmotility, severe, untreated psychiatric disease, and predominant complaints of bloating and/or abdominal pain.

In uncertain cases, the authors note a temporary diverting loop ileostomy may help predict the potential response to colectomy, but that a colectomy with ileorectal anastomosis should only be offered to patients without ongoing defecatory disorders.

Of note, the authors caution that even with careful assessment as outlined in the practice update, the decision to pursue surgery for refractory constipation should be made by an experienced clinician based on the preponderance of available evidence for a given patient without adhering to a strict algorithm.

Staller K, Neshatian L, Lembo A, Bharucha AE. AGA Clinical Practice Update on Evaluation and Management of Refractory Constipation: Expert Review. 

Clinical Gastroenterology and Hepatology. 

American Gastroenterological Association. New expert guidance urges caution before surgery for patients with treatment-resistant constipation. January 7, 2026. Accessed January 8, 2026. 

https://www.eurekalert.org/news-releases/1111165

International Foundation for Gastrointestinal Disorders. Chronic Constipation. Accessed January 8, 2026. 

https://iffgd.org/gi-disorders/lower-gi-disorders/constipation/

Brenner D. Real-World Data Highlight a New Approach to Chronic Constipation, With Darren Brenner, MD. December 15, 2025. Accessed January 8, 2026. 

https://www.hcplive.com/view/real-world-data-highlight-a-new-approach-to-chronic-constipation-with-darren-brenner-md

Refractory constipation, affecting a subset of patients unresponsive to standard treatments, poses significant healthcare challenges. The American Gastroenterological Association has issued a clinical practice update with 14 best-practice advice statements to guide clinicians in diagnosing and managing this condition. Recommendations include excluding secondary causes, confirming slow colonic transit, and ensuring comprehensive trials of available therapies. Surgical options, such as colectomy, are considered for non-responders but carry risks. Psychological evaluation is advised pre-surgery, and contraindications include upper-gut dysmotility and untreated psychiatric conditions.

The document outlines 14 best-practice advice statements for diagnosing and managing refractory constipation, with an emphasis on surgical intervention. 

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

AGA Urges Caution Around Surgery for Refractory Constipation in Clinical Practice Update

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A study links caregiver beliefs, mental health challenges, multiple allergens, and prior anaphylaxis to worse food allergy–related quality of life in pediatric patients.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Jasper Therapeutics has released new, positive findings on the use of briquilimab, a novel antibody therapy targeting KIT (CD117), in patients with CSU.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

BEACON: Positive Results Announced for Briquilimab in Chronic Spontaneous Urticaria

Mishaela Rubin, MD, MS, is a professor of medicine at Columbia University Irving Medical Center.

Videos

Rubin discusses an analysis of Ascendis’s program for patients who had received PTH treatment but weren’t eligible for clinical trials of palopegteriparatide.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Thyroid Disorders

Palopegteriparatide Allows for PTH Tapering in Hypoparathyroidism, With Mishaela Rubin, MD, MS

A trio of professional societies voice concerns about certain elements of the Dietary Guidelines for Americans, 2025–2030, and their potential negative health impacts.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

New Dietary Guidelines Draw Criticism For High Fat Dairy, Protein Recommendations

The FDA has not approved the sNDA for tasimelteon in jet lag disorder in its current form, citing positive efficacy but limited real-world applicability. 


Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

FDA Denies Tasimelteon’s Supplemental New Drug Application For Jet Lag Disorder

This video segment outlines the clinical features of familial chylomicronemia syndrome and introduces the emerging role of novel triglyceride-lowering therapies.

Video Series

 Understanding Updates in FCS Management with Newer Therapies

Clinically meaningful improvements in global IBS symptom severity were observed as early as week 1 and sustained through week 7.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

EBX-102-02 Shows Benefit for IBS-C and IBS-D in Phase 2a TrIuMPH Trial

This study evaluated the drug survival of different biologic therapies for patients with psoriasis in a routine clinical practice setting.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Ustekinumab Superior for Drug Survival to Other Psoriasis Biologics for Bio-Naïve

The Q4 recap for gastroenterology spotlights GI FDA news, new AGA guidelines, trial data for UC therapies, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Latest News

Q4 2025 Recap: Cardiology News and Updates

5 Rheumatology Headlines You Missed in December 2025

5 Pulmonology Headlines You Missed in December 2025

Depression's Implied Bilateral Link With Chronic Kidney Disease Progression

AGA Urges Caution Around Surgery for Refractory Constipation in Clinical Practice Update